title: Tumour-educated macrophages display a mixed polarisation and enhance pancreatic cancer cell invasion.
abstract: At the time of diagnosis, almost 80% of pancreatic cancer patients present with new-onset type 2 diabetes (T2D) or impaired glucose tolerance. T2D and pancreatic cancer are both associated with low-grade inflammation. Tumour-associated macrophages (TAMs) have a key role in cancer-related inflammation, immune escape, matrix remodelling and metastasis. In this study, the interplay between tumour cells and immune cells under the influence of different glucose levels was investigated. Human peripheral blood mononuclear cells were exposed in vitro to conditioned medium from BxPC-3 human pancreatic cancer cells, in normal (5 mM) or high (25 mM) glucose levels. Flow cytometry analyses demonstrated that tumour-derived factors stimulated differentiation of macrophages, with a mixed classical (M1-like) and alternatively activated (M2-like) phenotype polarisation (CD11c(+)CD206(+)). High-glucose conditions further enhanced the tumour-driven macrophage enrichment and associated interleukin (IL)-6 and IL-8 cytokine levels. In addition, hyperglycaemia enhanced the responsiveness of tumour-educated macrophages to lipopolysaccharide, with elevated cytokine secretion compared with normal glucose levels. Tumour-educated macrophages were found to promote pancreatic cancer cell invasion in vitro, which was significantly enhanced at high glucose. The anti-diabetic drug metformin shifted the macrophage phenotype polarisation and reduced the tumour cell invasion at normal, but not high, glucose levels. In conclusion, this study demonstrates that pancreatic cancer cells stimulate differentiation of macrophages with pro-tumour properties that are further enhanced by hyperglycaemia. These findings highlight important crosstalk between tumour cells and TAMs in the local tumour microenvironment that may contribute to disease progression in pancreatic cancer patients with hyperglycaemia and T2D.
authors.affiliation: Department of Surgery, Clinical Sciences Lund, Lund University, Lund, Sweden.
authors.forename: Emelie
authors.initials: E
authors.lastname: Karnevi
authors.affiliation: Department of Surgery, Clinical Sciences Lund, Lund University, Lund, Sweden.
authors.forename: Roland
authors.initials: R
authors.lastname: Andersson
authors.affiliation: 1] Department of Surgery, Clinical Sciences Lund, Lund University, Lund, Sweden [2] Department of Oncology, Clinical Sciences Lund, Skåne University Hospital, Lund University, Lund, Sweden.
authors.forename: Ann H
authors.initials: AH
authors.lastname: Rosendahl
mesh_terms: D039521:CD11c Antigen / Q000276:immunology; D045744:Cell Line, Tumor; D018920:Coculture Techniques; D003924:Diabetes Mellitus, Type 2 / Q000276:immunology / Q000473:pathology; D005260:Female; D005947:Glucose / Q000276:immunology; D006801:Humans; D006943:Hyperglycemia / Q000276:immunology / Q000473:pathology; D007004:Hypoglycemic Agents / Q000494:pharmacology; D015850:Interleukin-6 / Q000276:immunology; D016209:Interleukin-8 / Q000276:immunology; D037181:Lectins, C-Type / Q000276:immunology; D008264:Macrophages / Q000276:immunology* / Q000473:pathology; D008297:Male; D000090323:Mannose Receptor; D037241:Mannose-Binding Lectins / Q000276:immunology; D008687:Metformin / Q000494:pharmacology; D009361:Neoplasm Invasiveness; D010190:Pancreatic Neoplasms / Q000276:immunology* / Q000473:pathology; D011956:Receptors, Cell Surface / Q000276:immunology
chemical_list: D039521:CD11c Antigen; C508606:CXCL8 protein, human; D007004:Hypoglycemic Agents; C508600:IL6 protein, human; D015850:Interleukin-6; D016209:Interleukin-8; D037181:Lectins, C-Type; D000090323:Mannose Receptor; D037241:Mannose-Binding Lectins; D011956:Receptors, Cell Surface; D008687:Metformin; D005947:Glucose